Gilead Science公司比收入估计数高,投资公司持有的股份变动情况好坏参半。 Gilead Sciences beat earnings estimates, seeing mixed movements in investment firm holdings.

一些投资公司调整了在Gilead Science公司持有的股份,鹰石投资公司和Procyon顾问减少了股份,而第一国家公司MA ADV和Chesley Taft & Associates LLC增加了股份。 Several investment firms adjusted their holdings in Gilead Sciences, with Eagle Rock Investment and Procyon Advisors reducing their shares, while First National Corp MA ADV and Chesley Taft & Associates LLC increased theirs. 据Gilead Science公司报告,每股收入为1.81美元。 Gilead Sciences reported earnings of $1.81 per share, beating estimates. 该公司的股票开放额为112.46美元,市场上限为139.89亿美元,PE比率为303.95。 The company's stock opened at $112.46, with a market cap of $139.89 billion and a PE ratio of 303.95. 以治疗艾滋病毒/艾滋病和病毒性肝炎为主的Gile Science, 拥有“多价购买”评级和2.81%的红利收益。 Gilead Sciences, which focuses on treatments for HIV/AIDS and viral hepatitis, has a "Moderate Buy" rating and a dividend yield of 2.81%.